{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:39:33Z","timestamp":1773088773632,"version":"3.50.1"},"reference-count":362,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"am","delay-in-days":329,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.addr.2023.115161","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T11:55:01Z","timestamp":1703246101000},"page":"115161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Translation of cell therapies to treat autoimmune disorders"],"prefix":"10.1016","volume":"205","author":[{"given":"Jinal M.","family":"Mehta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivani C.","family":"Hiremath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chishiba","family":"Chilimba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azin","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-2443","authenticated-orcid":false,"given":"Jessica D.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2023.115161_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102423","article-title":"Comparative United States autoimmune disease rates for 2010\u20132016 by sex, geographic region, and race","volume":"19","author":"Roberts","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.addr.2023.115161_b0010","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.autrev.2012.02.001","article-title":"Updated assessment of the prevalence, spectrum and case definition of autoimmune disease","volume":"11","author":"Hayter","year":"2012","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.addr.2023.115161_b0015","first-page":"266","article-title":"The definition of autoimmune disease: are Koch\u2019s postulates applicable","volume":"60","author":"Damoiseaux","year":"2002","journal-title":"Neth J Med."},{"key":"10.1016\/j.addr.2023.115161_b0020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/01.NUMA.0000455740.32485.9c","article-title":"Autoimmune disease: Cost-effective care","volume":"45","author":"Julian","year":"2014","journal-title":"Nurs. Manage."},{"key":"10.1016\/j.addr.2023.115161_b0025","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1568-9972(03)00006-5","article-title":"The epidemiology of autoimmune diseases","volume":"2","author":"Cooper","year":"2003","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.addr.2023.115161_b0030","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.2105\/AJPH.2009.180273","article-title":"Burden of mortality associated with autoimmune diseases among females in the United Kingdom","volume":"100","author":"Thomas","year":"2010","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.addr.2023.115161_b0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","article-title":"Challenges, progress, and prospects of developing therapies to treat autoimmune diseases","volume":"181","author":"Fugger","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.addr.2023.115161_b0040","doi-asserted-by":"crossref","unstructured":"M. Mobasseri, M. Shirmohammadi, T. Amiri, N. Vahed, H. Hosseini Fard, M. Ghojazadeh, Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis, Health Promot Perspect. 10 (2020) 98\u2013115. 10.34172\/hpp.2020.18.","DOI":"10.34172\/hpp.2020.18"},{"key":"10.1016\/j.addr.2023.115161_b0045","unstructured":"The Cost of Diabetes | ADA, (n.d.). https:\/\/diabetes.org\/about-us\/statistics\/cost-diabetes (accessed September 12, 2023)."},{"key":"10.1016\/j.addr.2023.115161_b0050","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.addr.2023.115161_b0055","doi-asserted-by":"crossref","first-page":"e1810","DOI":"10.1212\/WNL.0000000000200150","article-title":"The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs","volume":"98","author":"Bebo","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.addr.2023.115161_b0060","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1741-7015-7-12","article-title":"Sex differences in rheumatoid arthritis: more than meets the eye","volume":"7","author":"van Vollenhoven","year":"2009","journal-title":"BMC Med."},{"key":"10.1016\/j.addr.2023.115161_b0065","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.23512","article-title":"Medical care costs associated with rheumatoid arthritis in the US: a systematic literature review and meta-analysis","volume":"70","author":"Hresko","year":"2018","journal-title":"Arthritis Care Res (hoboken)."},{"key":"10.1016\/j.addr.2023.115161_b0070","unstructured":"A. Rubio-Tapia, J.F. Ludvigsson, T.L. Brantner, J.A. Murray, J.E. Everhart, The prevalence of celiac disease in the United States, (n.d.). 10.1038\/ajg.2012.219."},{"key":"10.1016\/j.addr.2023.115161_b0075","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.14309\/ajg.0000000000000759","article-title":"Healthcare resource utilization and costs in celiac disease: A US claims analysis","volume":"115","author":"Cappell","year":"2020","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.addr.2023.115161_b0080","doi-asserted-by":"crossref","unstructured":"M.P.J. Vanderpump, W.M.G. Tunbrldge, Jm. French, D. Appleton, D. Bates, F. Clark, J.G. Evans, D.M. Hasan, H. Rodgers, F. Tunbridge, The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey, Clin. Endocrinol. 43 (1995) 55\u201368.","DOI":"10.1111\/j.1365-2265.1995.tb01894.x"},{"key":"10.1016\/j.addr.2023.115161_b0085","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1080\/13696998.2021.1900202","article-title":"The direct and indirect economic burden of hypothyroidism in the United States: a retrospective claims database study","volume":"24","author":"Hepp","year":"2021","journal-title":"J Med Econ."},{"key":"10.1016\/j.addr.2023.115161_b0090","doi-asserted-by":"crossref","first-page":"10554","DOI":"10.3390\/ijms221910554","article-title":"Endometriosis: Epidemiology, Classification, Pathogenesis, Treatment and Genetics (Review of Literature)","volume":"22","author":"Smolarz","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2023.115161_b0095","doi-asserted-by":"crossref","DOI":"10.3389\/fgwh.2022.902371","article-title":"Endometriosis Is Undervalued: A Call to Action","volume":"3","author":"Ellis","year":"2022","journal-title":"Front Glob Womens Health."},{"key":"10.1016\/j.addr.2023.115161_b0100","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1093\/rheumatology\/kex260","article-title":"The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies","volume":"56","author":"Rees","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.addr.2023.115161_b0105","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/808391","article-title":"Healthcare utilization and costs of systemic lupus erythematosus in Medicaid","volume":"2013","author":"Kan","year":"2013","journal-title":"Biomed Res Int."},{"key":"10.1016\/j.addr.2023.115161_b0110","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/90935","article-title":"Autoimmune disease: why and where it occurs","volume":"7","author":"Marrack","year":"2001","journal-title":"Nat Med."},{"key":"10.1016\/j.addr.2023.115161_b0115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1196\/annals.1254.017","article-title":"Autoimmune diseases as the loss of active \u201cself-control\u201d","volume":"998","author":"Bach","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.addr.2023.115161_b0120","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.autrev.2008.12.019","article-title":"The role of innate immune responses in autoimmune disease development","volume":"8","author":"Waldner","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.addr.2023.115161_b0125","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1056\/NEJMsr1715626","article-title":"Balancing Safety and Innovation for Cell-Based Regenerative Medicine","volume":"378","author":"Marks","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2023.115161_b0130","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/stem.37","article-title":"Deconstructing Stem Cell Tumorigenicity: A Roadmap to Safe Regenerative Medicine","volume":"27","author":"Knoepfler","year":"2009","journal-title":"Stem Cells"},{"key":"10.1016\/j.addr.2023.115161_b0135","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/EDE.0b013e31829ef01a","article-title":"The prevalence of type 1 diabetes in the United States","volume":"24","author":"Menke","year":"2013","journal-title":"Epidemiology"},{"key":"10.1016\/j.addr.2023.115161_b0140","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","article-title":"Type 1 diabetes","volume":"391","author":"DiMeglio","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2023.115161_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.756548","article-title":"Partners in crime: beta-cells and autoimmune responses complicit in type 1 diabetes pathogenesis","volume":"12","author":"Toren","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.addr.2023.115161_b0150","doi-asserted-by":"crossref","unstructured":"P. Achenbach, E. Bonifacio, A.J.K. Williams, A.G. Ziegler, E. a. M. Gale, P.J. Bingley, ENDIT Group, Autoantibodies to IA-2beta improve diabetes risk assessment in high-risk relatives, Diabetologia. 51 (2008) 488\u2013492. 10.1007\/s00125-007-0912-9.","DOI":"10.1007\/s00125-007-0912-9"},{"key":"10.1016\/j.addr.2023.115161_b0155","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2249.2012.04675.x","article-title":"Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients","volume":"171","author":"Gorus","year":"2013","journal-title":"Clin Exp Immunol."},{"key":"10.1016\/j.addr.2023.115161_b0160","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.2337\/db15-1058","article-title":"Identification of Tetraspanin-7 as a Target of Autoantibodies in Type 1 Diabetes","volume":"65","author":"McLaughlin","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2023.115161_b0165","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1126\/science.6362005","article-title":"Insulin antibodies in insulin-dependent diabetics before insulin treatment","volume":"222","author":"Palmer","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.addr.2023.115161_b0170","doi-asserted-by":"crossref","first-page":"17040","DOI":"10.1073\/pnas.0705894104","article-title":"The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes","volume":"104","author":"Wenzlau","year":"2007","journal-title":"Proc Natl Acad Sci U S a."},{"key":"10.1016\/j.addr.2023.115161_b0175","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/jc.2009-1365","article-title":"Clinical applications of diabetes antibody testing","volume":"95","author":"Bingley","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.addr.2023.115161_b0180","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2337\/dc15-1419","article-title":"Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association","volume":"38","author":"Insel","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2023.115161_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2023.06.018","article-title":"The pathogenic \u201csymphony\u201d in type 1 diabetes: A disorder of the immune system, \u03b2 cells, and exocrine pancreas","author":"Atkinson","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.addr.2023.115161_b0190","first-page":"14","article-title":"New Drug Delays Type 1 Diabetes Onset","volume":"329","author":"Larkin","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2023.115161_b0195","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S2213-8587(18)30112-8","article-title":"The challenge of modulating \u03b2-cell autoimmunity in type 1 diabetes","volume":"7","author":"Atkinson","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.addr.2023.115161_b0200","first-page":"1134","article-title":"The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families","volume":"59","author":"Noble","year":"1996","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.addr.2023.115161_b0205","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/dme.12099","article-title":"The environment and the origins of islet autoimmunity and Type 1 diabetes","volume":"30","author":"Eringsmark Regn\u00e9ll","year":"2013","journal-title":"Diabet. Med."},{"key":"10.1016\/j.addr.2023.115161_b0210","first-page":"149","article-title":"Viruses and type 1 diabetes: a new look at an old story","volume":"14","author":"Craig","year":"2013","journal-title":"Pediatr. Diabetes"},{"key":"10.1016\/j.addr.2023.115161_b0215","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s00125-019-4811-7","article-title":"Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes","volume":"62","author":"Dunne","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.addr.2023.115161_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(23)00122-5","article-title":"Enteroviruses and risk of islet autoimmunity or type 1 diabetes: systematic review and meta-analysis of controlled observational studies detecting viral nucleic acids and proteins","author":"Isaacs","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.addr.2023.115161_b0225","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1001\/jamapediatrics.2021.5801","article-title":"Incidence of new-onset type 1 diabetes among US children during the COVID-19 global pandemic","volume":"176","author":"Gottesman","year":"2022","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.addr.2023.115161_b0230","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/pedi.13328","article-title":"Increase in newly diagnosed type 1 diabetes in youth during the COVID-19 pandemic in the United States: A multi-center analysis","volume":"23","author":"Wolf","year":"2022","journal-title":"Pediatr. Diabetes"},{"key":"10.1016\/j.addr.2023.115161_b0235","doi-asserted-by":"crossref","first-page":"e2321231","DOI":"10.1001\/jamanetworkopen.2023.21231","article-title":"Elucidating the Underlying Mechanisms of the Marked Increase in Childhood Type 1 Diabetes During the COVID-19 Pandemic\u2014The Diabetes Pandemic","volume":"6","author":"Kamath","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.addr.2023.115161_b0240","doi-asserted-by":"crossref","first-page":"e2321281","DOI":"10.1001\/jamanetworkopen.2023.21281","article-title":"Incidence of Diabetes in Children and Adolescents During the COVID-19 Pandemic: A Systematic Review and Meta-Analysis","volume":"6","author":"D\u2019Souza","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.addr.2023.115161_b0245","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000493647","article-title":"Intralymphatic immunotherapy: update and unmet needs","volume":"178","author":"Senti","year":"2019","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.addr.2023.115161_b0250","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1196\/annals.1309.057","article-title":"Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes","volume":"1029","author":"Ergun-Longmire","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.addr.2023.115161_b0255","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMc1616343","article-title":"Intralymphatic Injection of Autoantigen in Type 1 Diabetes","volume":"376","author":"Ludvigsson","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.addr.2023.115161_b0260","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2217\/dmt.13.36","article-title":"Inducing immune tolerance: a focus on Type 1 diabetes mellitus","volume":"3","author":"Xu","year":"2013","journal-title":"Diabetes Manag (lond)."},{"key":"10.1016\/j.addr.2023.115161_b0265","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2023.115161_b0270","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1126\/science.abh1657","article-title":"Strategies for durable \u03b2 cell replacement in type 1 diabetes","volume":"373","author":"Brusko","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.addr.2023.115161_b0275","first-page":"68","article-title":"A spectacular year for islet and stem cell transplantation, Nature Reviews","volume":"19","author":"Shapiro","year":"2023","journal-title":"Endocrinology"},{"key":"10.1016\/j.addr.2023.115161_b0280","unstructured":"O. of the Commissioner, FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes, FDA. (2023). https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-cellular-therapy-treat-patients-type-1-diabetes (accessed July 8, 2023)."},{"key":"10.1016\/j.addr.2023.115161_b0285","article-title":"FDA approves first cell therapy for type 1 diabetes","author":"Mullard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2023.115161_b0290","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1007\/s00125-020-05367-2","article-title":"The promise of stem cell-derived islet replacement therapy","volume":"64","author":"Melton","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.addr.2023.115161_b0295","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1038\/s41596-021-00560-y","article-title":"Generation of insulin-producing pancreatic \u03b2 cells from multiple human stem cell lines","volume":"16","author":"Hogrebe","year":"2021","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2023.115161_b0300","first-page":"8","article-title":"First-in-Human Phase 1\/2 Clinical Trial of SIG-001, an Innovative Shielded Cell Therapy Platform, for Hemophilia \u0391","volume":"136","author":"Shapiro","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.addr.2023.115161_b0305","article-title":"Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device","volume":"2","author":"Shapiro","year":"2021","journal-title":"Cell Rep Med."},{"key":"10.1016\/j.addr.2023.115161_b0310","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.stem.2021.10.003","article-title":"Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes","volume":"28","author":"Ramzy","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.addr.2023.115161_b0315","unstructured":"Vertex Pharmaceuticals Incorporated, A Phase 1\/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia, clinicaltrials.gov, 2023. https:\/\/clinicaltrials.gov\/study\/NCT04786262 (accessed July 24, 2023)."},{"key":"10.1016\/j.addr.2023.115161_b0320","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/ajt.15168","article-title":"Synthetic poly(ethylene glycol)-based microfluidic islet encapsulation reduces graft volume for delivery to highly vascularized and retrievable transplant site","volume":"19","author":"Weaver","year":"2019","journal-title":"Am J Transplant."},{"key":"10.1016\/j.addr.2023.115161_b0325","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.biomaterials.2018.04.047","article-title":"Design of a vascularized synthetic poly(ethylene glycol) macroencapsulation device for islet transplantation","volume":"172","author":"Weaver","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2023.115161_b0330","first-page":"7014","article-title":"Biomaterial-based approaches to engineering immune tolerance, Biomaterials","volume":"8","author":"Emerson","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2023.115161_b0335","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1021\/acsbiomaterials.2c00640","article-title":"Hydrogel Injection Molding to Generate Complex Cell Encapsulation Geometries","volume":"8","author":"Emerson","year":"2022","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.addr.2023.115161_b0340","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41563-018-0099-0","article-title":"Local immunomodulation Fas ligand-engineered biomaterials achieves allogeneic islet graft acceptance","volume":"17","author":"Headen","year":"2018","journal-title":"Nat Mater."},{"key":"10.1016\/j.addr.2023.115161_b0345","first-page":"eaba5573","article-title":"Immunotherapy via PD-L1\u2013presenting biomaterials leads to long-term islet graft survival, Science","volume":"6","author":"Coronel","year":"2020","journal-title":"Advances"},{"key":"10.1016\/j.addr.2023.115161_b0350","doi-asserted-by":"crossref","first-page":"eadg5794","DOI":"10.1126\/scitranslmed.adg5794","article-title":"Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice","volume":"15","author":"Hu","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2023.115161_b0355","doi-asserted-by":"crossref","first-page":"e1700184","DOI":"10.1126\/sciadv.1700184","article-title":"Vasculogenic hydrogel enhances islet survival, engraftment, and function in leading extrahepatic sites","volume":"3","author":"Weaver","year":"2017","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2023.115161_b0360","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1177\/193229681000400525","article-title":"Enhancing clinical islet transplantation through tissue engineering strategies","volume":"4","author":"Giraldo","year":"2010","journal-title":"J Diabetes Sci Technol."},{"key":"10.1016\/j.addr.2023.115161_b0365","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1007\/s00125-016-4067-4","article-title":"Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes","volume":"59","author":"Richardson","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.addr.2023.115161_b0370","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2023.115161_b0375","first-page":"1","article-title":"Multiple Sclerosis: Pathogenesis","volume":"19","author":"Ghasemi","year":"2017","journal-title":"Symptoms, Diagnoses and Cell-Based Therapy, Cell J."},{"key":"10.1016\/j.addr.2023.115161_b0380","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00415-008-1002-8","article-title":"A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis","volume":"255","author":"Weiner","year":"2008","journal-title":"J Neurol."},{"key":"10.1016\/j.addr.2023.115161_b0385","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","article-title":"Immunology of Multiple Sclerosis","volume":"23","author":"Sospedra","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.addr.2023.115161_b0390","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.addr.2023.115161_b0395","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.addr.2023.115161_b0400","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41591-022-01823-1","article-title":"Guilty by association: Epstein-Barr virus in multiple sclerosis","volume":"28","author":"Bar-Or","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2023.115161_b0405","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202000650","article-title":"Multiple sclerosis risk variants regulate gene expression in innate and adaptive immune cells","volume":"3","author":"Gresle","year":"2020","journal-title":"Life Science Alliance."},{"key":"10.1016\/j.addr.2023.115161_b0410","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jneuroim.2009.10.015","article-title":"Role of the innate immune system in the pathogenesis of multiple sclerosis","volume":"221","author":"Gandhi","year":"2010","journal-title":"J Neuroimmunol."},{"key":"10.1016\/j.addr.2023.115161_b0415","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"The Lancet Neurology."},{"key":"10.1016\/j.addr.2023.115161_b0420","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1016\/j.febslet.2011.04.066","article-title":"How do immune cells overcome the blood\u2013brain barrier in multiple sclerosis?","volume":"585","author":"Larochelle","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.addr.2023.115161_b0425","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25927","article-title":"The role of B cells in Multiple Sclerosis and related disorders","volume":"89","author":"Comi","year":"2021","journal-title":"Ann Neurol."},{"key":"10.1016\/j.addr.2023.115161_b0430","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1756285613488434","article-title":"Sex and gender issues in multiple sclerosis","volume":"6","author":"Harbo","year":"2013","journal-title":"Ther Adv Neurol Disord."},{"key":"10.1016\/j.addr.2023.115161_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2020.101973","article-title":"Astrocytes and microglia in neurodegenerative diseases: Lessons from human in vitro models","volume":"200","author":"Franklin","year":"2021","journal-title":"Prog Neurobiol."},{"key":"10.1016\/j.addr.2023.115161_b0440","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/B978-0-12-802395-2.00019-5","article-title":"Inflammatory demyelinating diseases of the central nervous system","volume":"145","author":"H\u00f6ftberger","year":"2018","journal-title":"Handb Clin Neurol."},{"key":"10.1016\/j.addr.2023.115161_b0445","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1471-4159.2006.04232.x","article-title":"Multiple sclerosis: a battle between destruction and repair","volume":"100","author":"McQualter","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.addr.2023.115161_b0450","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2174\/157015911796557911","article-title":"Multiple Sclerosis: Pathogenesis and Treatment","volume":"9","author":"Loma","year":"2011","journal-title":"Curr Neuropharmacol."},{"key":"10.1016\/j.addr.2023.115161_b0455","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/joim.13215","article-title":"Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis","volume":"289","author":"Piehl","year":"2021","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.addr.2023.115161_b0460","unstructured":"M. Bornstein, S. Slagle, S. Weitzman, A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis, (n.d.). 10.1056\/nejm198708133170703."},{"key":"10.1016\/j.addr.2023.115161_b0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2021.104068","article-title":"Update on treatment in multiple sclerosis","volume":"50","author":"Callegari","year":"2021","journal-title":"Presse Med."},{"key":"10.1016\/j.addr.2023.115161_b0470","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2147\/TCRM.S282390","article-title":"<p>Ocrelizumab for the Treatment of Multiple Sclerosis: Safety","volume":"17","author":"Mancinelli","year":"2021","journal-title":"Efficacy, and Pharmacology<\/p>, TCRM."},{"key":"10.1016\/j.addr.2023.115161_b0475","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.00764","article-title":"Blood-Brain Barrier: More Contributor to Disruption of Central Nervous System Homeostasis Than Victim in Neurological Disorders","volume":"14","author":"Xiao","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.addr.2023.115161_b0480","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.neulet.2008.03.097","article-title":"Regeneration and repair in multiple sclerosis: The role of cell transplantation","volume":"456","author":"Pluchino","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.addr.2023.115161_b0485","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s13311-011-0065-x","article-title":"Myelin Regeneration in Multiple Sclerosis: Targeting Endogenous Stem Cells","volume":"8","author":"Huang","year":"2011","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.addr.2023.115161_b0490","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature12647","article-title":"A regenerative approach to the treatment of multiple sclerosis","volume":"502","author":"Deshmukh","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.addr.2023.115161_b0495","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000112359","article-title":"Transplantation of CNS fragments into the brain of shiverer mutant mice: Extensive myelination by implanted oligodendrocytes: I","volume":"6","author":"Lachapelle","year":"1983","journal-title":"Immunohistochemical Studies, Developmental Neuroscience."},{"key":"10.1016\/j.addr.2023.115161_b0500","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/362453a0","article-title":"Repair of demyelinated lesions by transplantation of purified 0\u20132A progenitor cells","volume":"362","author":"Groves","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.addr.2023.115161_b0505","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1431349","article-title":"GDNF enhances therapeutic efficiency of neural stem cells-based therapy in chronic experimental allergic encephalomyelitis in rat","volume":"2016","author":"Gao","year":"2016","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.addr.2023.115161_b0510","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1007\/s12035-016-9994-z","article-title":"LINGO-1-Fc-transduced neural stem cells are effective therapy for chronic stage experimental autoimmune encephalomyelitis","volume":"54","author":"Li","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.addr.2023.115161_b0515","first-page":"46","article-title":"Co-transplantation of human neurotrophic factor secreting cells and adipose-derived stem cells in rat model of multiple sclerosis","volume":"20","author":"Razavi","year":"2018","journal-title":"Cell Journal (yakhteh)."},{"key":"10.1016\/j.addr.2023.115161_b0520","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nature01552","article-title":"Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis","volume":"422","author":"Pluchino","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.addr.2023.115161_b0525","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/13524585211008760","article-title":"Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review","volume":"28","author":"Allanach","year":"2022","journal-title":"Mult Scler."},{"key":"10.1016\/j.addr.2023.115161_b0530","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrn1908","article-title":"The therapeutic potential of neural stem cells","volume":"7","author":"Martino","year":"2006","journal-title":"Nat Rev Neurosci."},{"key":"10.1016\/j.addr.2023.115161_b0535","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nature03889","article-title":"Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism","volume":"436","author":"Pluchino","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.addr.2023.115161_b0540","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1634\/stemcells.2007-0037","article-title":"Magnetic resonance-based tracking and quantification of intravenously injected neural stem cell accumulation in the brains of mice with experimental multiple sclerosis","volume":"25","author":"Politi","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.addr.2023.115161_b0545","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.mcn.2003.08.009","article-title":"Intraventricular transplantation of neural precursor cell spheres attenuates acute experimental allergic encephalomyelitis","volume":"24","author":"Einstein","year":"2003","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.addr.2023.115161_b0550","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/glia.10159","article-title":"Transplanted multipotential neural precursor cells migrate into the inflamed white matter in response to experimental autoimmune encephalomyelitis","volume":"41","author":"Ben-Hur","year":"2003","journal-title":"Glia"},{"key":"10.1016\/j.addr.2023.115161_b0555","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00019052-200406000-00003","article-title":"Cell-based remyelinating therapies in multiple sclerosis: evidence from experimental studies","volume":"17","author":"Pluchino","year":"2004","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.addr.2023.115161_b0560","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41591-022-02097-3","article-title":"Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study","volume":"29","author":"Genchi","year":"2023","journal-title":"Nat Med."},{"key":"10.1016\/j.addr.2023.115161_b0565","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.wco.0000073930.19076.1b","article-title":"Hematopoietic stem cell transplantation for multiple sclerosis: current status and future challenges","volume":"16","author":"Muraro","year":"2003","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.addr.2023.115161_b0570","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/glia.20127","article-title":"Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation","volume":"49","author":"Nistor","year":"2005","journal-title":"Glia"},{"key":"10.1016\/j.addr.2023.115161_b0575","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1634\/stemcells.2007-0637","article-title":"Concise review: mesenchymal stem\/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair\u2014current views","volume":"25","author":"Phinney","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.addr.2023.115161_b0580","doi-asserted-by":"crossref","first-page":"10711","DOI":"10.1073\/pnas.96.19.10711","article-title":"Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains","volume":"96","author":"Kopen","year":"1999","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2023.115161_b0585","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1089\/scd.2007.0197","article-title":"Neuronal differentiation potential of human adipose-derived mesenchymal stem cells","volume":"17","author":"Anghileri","year":"2008","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.addr.2023.115161_b0590","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood-2005-04-1496","article-title":"Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy","volume":"106","author":"Zappia","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.addr.2023.115161_b0595","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archneur.65.6.753","article-title":"Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis","volume":"65","author":"Kassis","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.addr.2023.115161_b0600","first-page":"219","article-title":"Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis, Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology","volume":"61","author":"Gerdoni","year":"2007","journal-title":"Society"},{"key":"10.1016\/j.addr.2023.115161_b0605","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/glia.20841","article-title":"Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis","volume":"57","author":"Bai","year":"2009","journal-title":"Glia"},{"key":"10.1016\/j.addr.2023.115161_b0610","doi-asserted-by":"crossref","unstructured":"D.P.J. Hunt, K.A. Irvine, D.J. Webber, D.A.S. Compston, W.F. Blakemore, S. Chandran, Effects of direct transplantation of multipotent mesenchymal stromal\/stem cells into the demyelinated spinal cord, (2008).","DOI":"10.3727\/096368908786516738"},{"key":"10.1016\/j.addr.2023.115161_b0615","doi-asserted-by":"crossref","first-page":"e2062","DOI":"10.1038\/cddis.2015.327","article-title":"Mesenchymal stem cells and immunomodulation: current status and future prospects","volume":"7","author":"Gao","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.addr.2023.115161_b0620","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41536-021-00199-z","article-title":"OCT4-induced oligodendrocyte progenitor cells promote remyelination and ameliorate disease","volume":"7","author":"Yun","year":"2022","journal-title":"npj Regener. Med."},{"key":"10.1016\/j.addr.2023.115161_b0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102400","article-title":"The etiology of rheumatoid arthritis","volume":"110","author":"Scherer","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.addr.2023.115161_b0630","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The Pathogenesis of Rheumatoid Arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2023.115161_b0635","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1186\/ar575","article-title":"Angiogenesis in rheumatoid arthritis","volume":"4","author":"Paleolog","year":"2002","journal-title":"Arthritis Res."},{"key":"10.1016\/j.addr.2023.115161_b0640","unstructured":"E. Lubberts, W.B. van den Berg, Cytokines in the Pathogenesis of Rheumatoid Arthritis and Collagen-Induced Arthritis, in: Madame Curie Bioscience Database [Internet], Landes Bioscience, 2013. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK6288\/ (accessed June 14, 2023)."},{"key":"10.1016\/j.addr.2023.115161_b0645","doi-asserted-by":"crossref","first-page":"10922","DOI":"10.3390\/ijms222010922","article-title":"Cytokine Networks in the Pathogenesis of Rheumatoid Arthritis","volume":"22","author":"Kondo","year":"2021","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.addr.2023.115161_b0650","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1186\/ar572","article-title":"Matrix metalloproteinases in arthritic disease","volume":"4","author":"Murphy","year":"2002","journal-title":"Arthritis Res."},{"key":"10.1016\/j.addr.2023.115161_b0655","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052871","article-title":"Inflammation and Bone Metabolism in Rheumatoid Arthritis: Molecular Mechanisms of Joint Destruction and Pharmacological Treatments","volume":"23","author":"Maeda","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2023.115161_b0660","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41598-018-37448-z","article-title":"High percentages and activity of synovial fluid NK cells present in patients with advanced stage active Rheumatoid Arthritis","volume":"9","author":"Yamin","year":"2019","journal-title":"Sci Rep."},{"key":"10.1016\/j.addr.2023.115161_b0665","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar1010","article-title":"Roles of B cells in rheumatoid arthritis","volume":"5","author":"Silverman","year":"2003","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.addr.2023.115161_b0670","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/qjmed\/hcp165","article-title":"Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies","volume":"103","author":"Song","year":"2010","journal-title":"QJM"},{"key":"10.1016\/j.addr.2023.115161_b0675","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jmii.2016.11.010","article-title":"High levels of soluble GPR56\/ADGRG1 are associated with positive rheumatoid factor and elevated tumor necrosis factor in patients with rheumatoid arthritis","volume":"51","author":"Tseng","year":"2018","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.addr.2023.115161_b0680","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.24827","article-title":"Anti-Citrullinated Peptide Antibody (ACPA) Assays and their Role in the Diagnosis of Rheumatoid Arthritis","volume":"61","author":"Aggarwal","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2023.115161_b0685","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jbspin.2017.07.009","article-title":"Anti -citrullinated peptide antibodies profiling in established rheumatoid arthritis","volume":"85","author":"Manca","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.addr.2023.115161_b0690","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","article-title":"Novel treatment strategies in rheumatoid arthritis","volume":"389","author":"Burmester","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2023.115161_b0695","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3899\/jrheum.091131","article-title":"Remission in Early Rheumatoid Arthritis","volume":"37","author":"Ma","year":"2010","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.addr.2023.115161_b0700","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(09)60944-2","article-title":"Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial","volume":"374","author":"Van Vollenhoven","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2023.115161_b0705","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/2040622312466908","article-title":"Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy","volume":"4","author":"Kaneko","year":"2013","journal-title":"Ther Adv Chronic Dis."},{"key":"10.1016\/j.addr.2023.115161_b0710","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/DDDT.S41645","article-title":"Rituximab for the treatment of rheumatoid arthritis: an update","volume":"8","author":"Mok","year":"2013","journal-title":"Drug Des Devel Ther."},{"key":"10.1016\/j.addr.2023.115161_b0715","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s10875-012-9849-y","article-title":"Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease","volume":"33","author":"Yokoyama","year":"2013","journal-title":"J Clin Immunol."},{"key":"10.1016\/j.addr.2023.115161_b0720","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.mayocp.2017.05.009","article-title":"Prediction of Response to Targeted Treatment in Rheumatoid Arthritis","volume":"92","author":"Wijbrandts","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.addr.2023.115161_b0725","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"The risk of serious infection with biologics in treating patients with rheumatoid arthritis: A Systematic Review and Meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2023.115161_b0730","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5114\/reum.2018.75523","article-title":"Cartilage and bone damage in rheumatoid arthritis","volume":"56","author":"Ostrowska","year":"2018","journal-title":"Reumatologia"},{"key":"10.1016\/j.addr.2023.115161_b0735","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.biomaterials.2016.01.024","article-title":"Biofabrication of bone tissue: approaches, challenges and translation for bone regeneration","volume":"83","author":"Tang","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2023.115161_b0740","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41536-019-0074-7","article-title":"Emerging therapies for cartilage regeneration in currently excluded \u2018red knee\u2019populations","volume":"4","author":"Mart\u00edn","year":"2019","journal-title":"npj Regener. Med."},{"key":"10.1016\/j.addr.2023.115161_b0745","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/jor.20502","article-title":"Matrix-induced autologous chondrocyte implantation in sheep: objective assessments including confocal arthroscopy","volume":"26","author":"Jones","year":"2008","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.addr.2023.115161_b0750","doi-asserted-by":"crossref","DOI":"10.1177\/2325967120973052","article-title":"Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cell Implantation Versus Microfracture for Large, Full-Thickness Cartilage Defects in Older Patients: A Multicenter Randomized Clinical Trial and Extended 5-Year Clinical Follow-up","volume":"9","author":"Lim","year":"2021","journal-title":"Orthop. J. Sports Med."},{"key":"10.1016\/j.addr.2023.115161_b0755","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41536-018-0055-2","article-title":"Trends in clinical trials for articular cartilage repair by cell therapy","volume":"3","author":"Negoro","year":"2018","journal-title":"npj Regener. Med."},{"key":"10.1016\/j.addr.2023.115161_b0760","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/bioengineering6010022","article-title":"Regenerative medicine: a review of the evolution of autologous chondrocyte implantation (ACI) therapy","volume":"6","author":"Davies","year":"2019","journal-title":"Bioengineering"},{"key":"10.1016\/j.addr.2023.115161_b0765","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3390\/jcm9010139","article-title":"Bone regeneration, reconstruction and use of osteogenic cells; from basic knowledge, animal models to clinical trials","volume":"9","author":"Hutchings","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.addr.2023.115161_b0770","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2015.01.044","article-title":"Celiac disease","volume":"135","author":"Green","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.addr.2023.115161_b0775","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1172\/JCI30253","article-title":"Celiac disease: pathogenesis of a model immunogenetic disease","volume":"117","author":"Kagnoff","year":"2007","journal-title":"J Clin Invest."},{"key":"10.1016\/j.addr.2023.115161_b0780","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4291\/wjgp.v8.i2.27","article-title":"Celiac disease: From pathophysiology to treatment","volume":"8","author":"Parzanese","year":"2017","journal-title":"World J Gastrointest Pathophysiol."},{"key":"10.1016\/j.addr.2023.115161_b0785","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/iep.12199","article-title":"Coeliac disease: immunogenicity studies of barley hordein and rye secalin-derived peptides","volume":"97","author":"Wahab","year":"2016","journal-title":"Int J Exp Pathol."},{"key":"10.1016\/j.addr.2023.115161_b0790","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/B978-0-12-416039-2.00013-6","article-title":"Oral enzyme therapy for celiac sprue","volume":"502","author":"Bethune","year":"2012","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.addr.2023.115161_b0795","doi-asserted-by":"crossref","first-page":"9254","DOI":"10.3390\/ijms21239254","article-title":"Secretory IgA in Intestinal Mucosal Secretions as an Adaptive Barrier against Microbial Cells","volume":"21","author":"Pietrzak","year":"2020","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.addr.2023.115161_b0800","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0140-6736(09)60254-3","article-title":"Coeliac disease","volume":"373","author":"Sabatino","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2023.115161_b0805","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40348-015-0029-z","article-title":"Endocytosis and transcytosis of gliadin peptides","volume":"3","author":"Barone","year":"2016","journal-title":"Mol Cell Pediatr."},{"key":"10.1016\/j.addr.2023.115161_b0810","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.4049\/jimmunol.173.6.3660","article-title":"Fas-Fas Ligand Interactions Are Essential for the Binding to and Killing of Activated Macrophages by \u03b3\u03b4 T Cells","volume":"173","author":"Dalton","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2023.115161_b0815","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.immuni.2004.06.018","article-title":"A Direct Role for NKG2D\/MICA Interaction in Villous Atrophy during Celiac Disease","volume":"21","author":"H\u00fce","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2023.115161_b0820","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/apt.12893","article-title":"Histological recovery and gluten-free diet adherence: a prospective 1-year follow-up study of adult patients with coeliac disease","volume":"40","author":"Galli","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2023.115161_b0825","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/j.gastro.2021.04.031","article-title":"The Promise of Novel Therapies to Abolish Gluten Immunogenicity in Celiac Disease","volume":"161","author":"Cerf-Bensussan","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2023.115161_b0830","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.gastro.2021.03.019","article-title":"Gluten degradation, pharmacokinetics, safety, and tolerability of TAK-062, an engineered enzyme to treat celiac disease","volume":"161","author":"Pultz","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2023.115161_b0835","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1053\/j.gastro.2008.09.016","article-title":"Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium","volume":"136","author":"Pinier","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2023.115161_b0840","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41586-020-2003-8","article-title":"IL-15, gluten and HLA-DQ8 drive tissue destruction in coeliac disease","volume":"578","author":"Abadie","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2023.115161_b0845","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.gastro.2021.03.014","article-title":"TAK-101 nanoparticles induce gluten-specific tolerance in celiac disease: a randomized, double-blind, placebo-controlled study","volume":"161","author":"Kelly","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2023.115161_b0850","first-page":"9967","article-title":"Adipose-Derived Stem Cells in the Treatment of Perianal Fistulas in Crohn\u2019s Disease: Rationale","volume":"22","author":"Buscail","year":"2021","journal-title":"Clinical Results and Perspectives, Int J Mol Sci."},{"key":"10.1016\/j.addr.2023.115161_b0855","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/nm.2695","article-title":"Functional engraftment of colon epithelium expanded in vitro from a single adult Lgr5+ stem cell","volume":"18","author":"Yui","year":"2012","journal-title":"Nat Med."},{"key":"10.1016\/j.addr.2023.115161_b0860","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1101\/gad.245233.114","article-title":"Small intestinal stem cell identity is maintained with functional Paneth cells in heterotopically grafted epithelium onto the colon","volume":"28","author":"Fukuda","year":"2014","journal-title":"Genes Dev."},{"key":"10.1016\/j.addr.2023.115161_b0865","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.stem.2013.09.015","article-title":"Transplantation of Expanded Fetal Intestinal Progenitors Contributes to Colon Regeneration after Injury","volume":"13","author":"Fordham","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.addr.2023.115161_b0870","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.stemcr.2018.12.001","article-title":"Nonadhesive alginate hydrogels support growth of pluripotent stem cell-derived intestinal organoids","volume":"12","author":"Capeling","year":"2019","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.addr.2023.115161_b0875","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/ncb3632","article-title":"Synthetic hydrogels for human intestinal organoid generation and colonic wound repair","volume":"19","author":"Cruz-Acu\u00f1a","year":"2017","journal-title":"Nat Cell Biol."},{"key":"10.1016\/j.addr.2023.115161_b0880","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1210\/er.2013-1055","article-title":"Breaking Tolerance to Thyroid Antigens: Changing Concepts in Thyroid Autoimmunity","volume":"35","author":"McLachlan","year":"2014","journal-title":"Endocr Rev."},{"key":"10.1016\/j.addr.2023.115161_b0885","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/clin.1997.4412","article-title":"Epidemiology and estimated population burden of selected autoimmune diseases in the United States","volume":"84","author":"Jacobson","year":"1997","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.addr.2023.115161_b0890","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.autrev.2014.10.016","article-title":"Autoimmune thyroid disorders","volume":"14","author":"Antonelli","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.addr.2023.115161_b0895","first-page":"e210024","article-title":"Cellular and molecular basis of thyroid autoimmunity","volume":"11","author":"Bogus\u0142awska","year":"2021","journal-title":"Eur Thyroid J."},{"key":"10.1016\/j.addr.2023.115161_b0900","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101367","article-title":"Hashimotos\u2019 thyroiditis: Epidemiology, pathogenesis, clinic and therapy","volume":"33","author":"Ragusa","year":"2019","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.addr.2023.115161_b0905","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101387","article-title":"Graves\u2019 disease: Epidemiology, genetic and environmental risk factors and viruses","volume":"34","author":"Antonelli","year":"2020","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.addr.2023.115161_b0910","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/nri2394","article-title":"The X-files in immunity: sex-based differences predispose immune responses","volume":"8","author":"Fish","year":"2008","journal-title":"Nat Rev Immunol."},{"key":"10.1016\/j.addr.2023.115161_b0915","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1089\/thy.2014.0318","article-title":"The Relationship Between Skewed X Chromosome Inactivation and the Prognosis of Graves\u2019 and Hashimoto\u2019s Diseases","volume":"25","author":"Ishido","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.addr.2023.115161_b0920","doi-asserted-by":"crossref","unstructured":"J. Klubo-Gwiezdzinska, L. Wartofsky, Hashimoto thyroiditis: an evidence-based guide to etiology, diagnosis and treatment, Pol Arch Intern Med. 132 (2022) 16222. 10.20452\/pamw.16222.","DOI":"10.20452\/pamw.16222"},{"key":"10.1016\/j.addr.2023.115161_b0925","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00228-015-1832-0","article-title":"Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide","volume":"71","author":"Tamargo","year":"2015","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.addr.2023.115161_b0930","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1210\/clinem\/dgaa646","article-title":"Management of Graves Thyroidal and Extrathyroidal Disease: An Update","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.addr.2023.115161_b0935","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/thy.2011.2106.ed3","article-title":"The American Thyroid Association\/American Association of Clinical Endocrinologists Guidelines for Hyperthyroidism and Other Causes of Thyrotoxicosis: A European Perspective","volume":"21","author":"Kahaly","year":"2011","journal-title":"Thyroid"},{"issue":"2018","key":"10.1016\/j.addr.2023.115161_b0940","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000490384","article-title":"European Thyroid Association Guideline for the Management of Graves\u2019 Hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"European Thyroid Journal."},{"key":"10.1016\/j.addr.2023.115161_b0945","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 Disease","volume":"375","author":"Smith","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2023.115161_b0950","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.666565","article-title":"Derivation of Thyroid Follicular Cells From Pluripotent Stem Cells: Insights From Development and Implications for Regenerative Medicine","volume":"12","author":"Posabella","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.addr.2023.115161_b0955","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1210\/en.2002-0122","article-title":"Committing embryonic stem cells to differentiate into thyrocyte-like cells in vitro","volume":"144","author":"Lin","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.addr.2023.115161_b0960","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1210\/en.2005-1239","article-title":"Directed differentiation of mouse embryonic stem cells into thyroid follicular cells","volume":"147","author":"Arufe","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.addr.2023.115161_b0965","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbrc.2009.02.035","article-title":"Differentiation of murine embryonic stem cells to thyrocytes requires insulin and insulin-like growth factor-1","volume":"381","author":"Arufe","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.addr.2023.115161_b0970","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1210\/en.2008-1374","article-title":"Thyrotropin-independent induction of thyroid endoderm from embryonic stem cells by activin A","volume":"150","author":"Ma","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.addr.2023.115161_b0975","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/nature11525","article-title":"Generation of functional thyroid from embryonic stem cells","volume":"491","author":"Antonica","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.addr.2023.115161_b0980","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1089\/thy.2012.0644","article-title":"Thyroid follicle formation and thyroglobulin expression in multipotent endodermal stem cells","volume":"23","author":"Ma","year":"2013","journal-title":"Thyroid"},{"key":"10.1016\/j.addr.2023.115161_b0985","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.stem.2015.09.004","article-title":"Regeneration of thyroid function by transplantation of differentiated pluripotent stem cells","volume":"17","author":"Kurmann","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.addr.2023.115161_b0990","first-page":"2003","article-title":"First Thymus Tissue Product Approved for Rare Disease","volume":"326","author":"Rubin","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2023.115161_b0995","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5114\/reum.2018.74750","article-title":"Quality of life in systemic lupus erythematosus and its measurement","volume":"56","author":"Olesi\u0144ska","year":"2018","journal-title":"Reumatologia"},{"key":"10.1016\/j.addr.2023.115161_b1000","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.fertnstert.2011.05.090","article-title":"Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries","volume":"96","author":"K.E. Nnoaham, L. Hummelshoj, P. Webster, T. d\u2019Hooghe, F. de Cicco Nardone, C. de Cicco Nardone, C. Jenkinson, S.H. Kennedy, K.T. Zondervan, W.E.R.F.G. Study","year":"2011","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.addr.2023.115161_b1005","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/art.40396","article-title":"Abnormal B cell development in systemic lupus erythematosus: what the genetics tell us","volume":"70","author":"Karrar","year":"2018","journal-title":"Arthritis & Rheumatology (hoboken, Nj)."},{"key":"10.1016\/j.addr.2023.115161_b1010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0961203310382429","article-title":"The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus?","volume":"20","author":"Narshi","year":"2011","journal-title":"Lupus"},{"issue":"2019","key":"10.1016\/j.addr.2023.115161_b1015","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.addr.2023.115161_b1020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/138945009787122833","article-title":"Monoclonal antibodies in the treatment of systemic lupus erythematosus","volume":"10","author":"Robak","year":"2009","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.addr.2023.115161_b1025","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/humrep\/des073","article-title":"The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres","volume":"27","author":"Simoens","year":"2012","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.addr.2023.115161_b1030","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0015-0282(01)01878-7","article-title":"Treating endometriosis as an autoimmune disease","volume":"76","author":"Nothnick","year":"2001","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.addr.2023.115161_b1035","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1055\/s-0033-1350890","article-title":"Surgical Therapy of Endometriosis: Challenges and Controversies","volume":"73","author":"Rimbach","year":"2013","journal-title":"Geburtshilfe Frauenheilkd."},{"key":"10.1016\/j.addr.2023.115161_b1040","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrendo.2013.255","article-title":"Endometriosis: pathogenesis and treatment","volume":"10","author":"Vercellini","year":"2014","journal-title":"Nat Rev Endocrinol."},{"key":"10.1016\/j.addr.2023.115161_b1045","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108435","article-title":"Prolactin and pain of endometriosis","volume":"247","author":"Lee","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.addr.2023.115161_b1050","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1067\/mob.2000.104804","article-title":"Gonadotropin-releasing hormone analog repairs reduced endometrial cell apoptosis in endometriosis in vitro","volume":"182","author":"Imai","year":"2000","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.addr.2023.115161_b1055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jri.2023.103814","article-title":"The effects of Rituximab on experimental endometriosis model in rats","volume":"156","author":"Dogan","year":"2023","journal-title":"J. Reprod. Immunol."},{"key":"10.1016\/j.addr.2023.115161_b1060","doi-asserted-by":"crossref","unstructured":"A.S. Mao, D.J. Mooney, Regenerative medicine: Current therapies and future directions, Proceedings of the National Academy of Sciences. 112 (2015) 14452\u201314459. 10.1073\/pnas.1508520112.","DOI":"10.1073\/pnas.1508520112"},{"key":"10.1016\/j.addr.2023.115161_b1065","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/172603a0","article-title":"\u2018Actively acquired tolerance\u2019of foreign cells","volume":"172","author":"Billingham","year":"1953","journal-title":"Nature"},{"key":"10.1016\/j.addr.2023.115161_b1070","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.autrev.2005.06.003","article-title":"Hematopoietic stem cell transplantation (HSCT): An approach to autoimmunity","volume":"5","author":"Alaez","year":"2006","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.addr.2023.115161_b1075","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nm0298-153","article-title":"BMT beats autoimmune disease","volume":"4","author":"Krance","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2023.115161_b1080","first-page":"244","article-title":"Haematopoietic stem cell transplantation for autoimmune diseases, Nature Reviews","volume":"13","author":"Swart","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.addr.2023.115161_b1085","first-page":"391","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis, Nature Reviews","volume":"13","author":"Muraro","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.addr.2023.115161_b1090","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2018.18743","article-title":"Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial","volume":"321","author":"Burt","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2023.115161_b1095","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.coi.2005.09.002","article-title":"How do CD4+ CD25+ regulatory T cells control autoimmunity?","volume":"17","author":"Bluestone","year":"2005","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.addr.2023.115161_b1100","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.4049\/jimmunol.177.3.1451","article-title":"Suppression of disease in New Zealand Black\/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells","volume":"177","author":"Scalapino","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2023.115161_b1105","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10753-017-0704-4","article-title":"Adoptive Induced Antigen-Specific Treg Cells Reverse Inflammation in Collagen-Induced Arthritis Mouse Model","volume":"41","author":"Sun","year":"2018","journal-title":"Inflammation"},{"key":"10.1016\/j.addr.2023.115161_b1110","doi-asserted-by":"crossref","unstructured":"G.P. Wright, C.A. Notley, S.-A. Xue, G.M. Bendle, A. Holler, T.N. Schumacher, M.R. Ehrenstein, H.J. Stauss, Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis, Proceedings of the National Academy of Sciences. 106 (2009) 19078\u201319083. 10.1073\/pnas.0907396106.","DOI":"10.1073\/pnas.0907396106"},{"key":"10.1016\/j.addr.2023.115161_b1115","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.4049\/jimmunol.169.9.4712","article-title":"Cutting edge: CD4+ CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis","volume":"169","author":"Kohm","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2023.115161_b1120","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.4049\/jimmunol.175.5.3053","article-title":"Expansion of functional endogenous antigen-specific CD4+ CD25+ regulatory T cells from nonobese diabetic mice","volume":"175","author":"Masteller","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2023.115161_b1125","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood-2005-08-3088","article-title":"Physiologic self antigens rapidly capacitate autoimmune disease-specific polyclonal CD4+ CD25+ regulatory T cells","volume":"107","author":"Setiady","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.addr.2023.115161_b1130","doi-asserted-by":"crossref","unstructured":"J.A. Bluestone, Q. Tang, Therapeutic vaccination using CD4+ CD25+ antigen-specific regulatory T cells, Proceedings of the National Academy of Sciences. 101 (2004) 14622\u201314626.","DOI":"10.1073\/pnas.0405234101"},{"key":"10.1016\/j.addr.2023.115161_b1135","article-title":"Regulatory T cells for minimising immune suppression in kidney transplantation: phase I\/IIa clinical trial","volume":"371","author":"Roemhild","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.addr.2023.115161_b1140","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1038\/s41598-018-25574-7","article-title":"A phase I clinical trial with ex vivo expanded recipient regulatory T cells in living donor kidney transplants","volume":"8","author":"Mathew","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2023.115161_b1145","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.3390\/ijms24097797","article-title":"Enhancing Regulatory T Cells to Treat Inflammatory and Autoimmune Diseases","volume":"24","author":"Fiyouzi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2023.115161_b1150","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.intimp.2009.01.032","article-title":"Clinical grade production of IL-10 producing regulatory Tr1 lymphocytes for cell therapy of chronic inflammatory diseases","volume":"9","author":"Brun","year":"2009","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.addr.2023.115161_b1155","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2023.115161_b1160","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/dc12-0038","article-title":"Administration of CD4+ CD25highCD127- regulatory T cells preserves \u03b2-cell function in type 1 diabetes in children","volume":"35","author":"Marek-Trzonkowska","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2023.115161_b1165","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clim.2014.03.016","article-title":"Therapy of type 1 diabetes with CD4+ CD25highCD127-regulatory T cells prolongs survival of pancreatic islets\u2014Results of one year follow-up","volume":"153","author":"Marek-Trzonkowska","year":"2014","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.addr.2023.115161_b1170","doi-asserted-by":"crossref","unstructured":"S. Dong, K.J. Hiam-Galvez, C.T. Mowery, K.C. Herold, S.E. Gitelman, J.H. Esensten, W. Liu, A.P. Lares, A.S. Leinbach, M. Lee, V. Nguyen, S.J. Tamaki, W. Tamaki, C.M. Tamaki, M. Mehdizadeh, A.L. Putnam, M.H. Spitzer, C.J. Ye, Q. Tang, J.A. Bluestone, The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes, JCI Insight. 6 (n.d.) e147474. 10.1172\/jci.insight.147474.","DOI":"10.1172\/jci.insight.147474"},{"key":"10.1016\/j.addr.2023.115161_b1175","first-page":"2183","article-title":"CAR T cell therapy: A new era for cancer treatment (Review)","volume":"42","author":"Mohanty","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.addr.2023.115161_b1180","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.addr.2023.115161_b1185","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jaut.2018.08.004","article-title":"Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes","volume":"96","author":"Zhang","year":"2019","journal-title":"J Autoimmun."},{"key":"10.1016\/j.addr.2023.115161_b1190","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/nbt758","article-title":"Targeting autoantigen-specific T cells and suppression of autoimmune encephalomyelitis with receptor-modified T lymphocytes","volume":"20","author":"Jyothi","year":"2002","journal-title":"Nat Biotechnol."},{"key":"10.1016\/j.addr.2023.115161_b1195","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaut.2018.05.003","article-title":"Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells","volume":"92","author":"Kim","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.addr.2023.115161_b1200","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflammation."},{"key":"10.1016\/j.addr.2023.115161_b1205","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104222","article-title":"Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression","volume":"358","author":"De Paula Pohl","year":"2020","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.addr.2023.115161_b1210","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/stem.1452","article-title":"Concise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots?","volume":"31","author":"Griffin","year":"2013","journal-title":"Stem Cells"},{"key":"10.1016\/j.addr.2023.115161_b1215","first-page":"563","volume":"47","author":"Liu","year":"2019","journal-title":"Meta-Analysis of Preclinical Studies of Mesenchymal Stromal Cells to Treat Rheumatoid Arthritis, eBioMedicine."},{"key":"10.1016\/j.addr.2023.115161_b1220","doi-asserted-by":"crossref","first-page":"993","DOI":"10.4049\/jimmunol.0900803","article-title":"Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes","volume":"183","author":"Fiorina","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2023.115161_b1225","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00125-009-1374-z","article-title":"Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells","volume":"52","author":"Madec","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.addr.2023.115161_b1230","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.2337\/db10-0542","article-title":"Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes","volume":"59","author":"Jurewicz","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2023.115161_b1235","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13287-019-1538-9","article-title":"Efficacy of mesenchymal stem cells in animal models of lupus nephritis: a meta-analysis","volume":"11","author":"Zhou","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.addr.2023.115161_b1240","doi-asserted-by":"crossref","first-page":"8662","DOI":"10.3390\/ijms21228662","article-title":"Mesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical Studies","volume":"21","author":"Gugliandolo","year":"2020","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.addr.2023.115161_b1245","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.891514","article-title":"Safety and Clinical Efficacy of Mesenchymal Stem Cell Treatment in Traumatic Spinal Cord Injury, Multiple Sclerosis and Ischemic Stroke \u2013 A Systematic Review and Meta-Analysis","volume":"13","author":"Kvistad","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.addr.2023.115161_b1250","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3727\/096368914X685005","article-title":"The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis","volume":"23","author":"Li","year":"2014","journal-title":"Cell Transplant."},{"key":"10.1016\/j.addr.2023.115161_b1255","doi-asserted-by":"crossref","first-page":"e113936","DOI":"10.1371\/journal.pone.0113936","article-title":"Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis","volume":"9","author":"Llufriu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2023.115161_b1260","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.msard.2014.08.002","article-title":"Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study","volume":"3","author":"Lublin","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.addr.2023.115161_b1265","first-page":"212","article-title":"Umbilical cord mesenchymal stem cell transplantation in the treatment of multiple sclerosis","volume":"10","author":"Meng","year":"2018","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.addr.2023.115161_b1270","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1474-4422(21)00301-X","article-title":"Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial","volume":"20","author":"Uccelli","year":"2021","journal-title":"The Lancet Neurology."},{"key":"10.1016\/j.addr.2023.115161_b1275","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1093\/brain\/awaa333","article-title":"Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis","volume":"143","author":"Petrou","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.addr.2023.115161_b1280","unstructured":"A.B.M. MOHY, M.K. ALI, A. GHAVAMZADEH, S. YAZDANBAKHSH, J. LOTFI, F. TALEBIAN, B. Nikbin, F. HOUSHMAND, Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study, (2007)."},{"key":"10.1016\/j.addr.2023.115161_b1285","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2174\/157488812804484648","article-title":"Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study","volume":"7","author":"Mohyeddin Bonab","year":"2012","journal-title":"Curr. Stem Cell Res. Ther."},{"key":"10.1016\/j.addr.2023.115161_b1290","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jneuroim.2010.07.013","article-title":"Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study","volume":"227","author":"Yamout","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.addr.2023.115161_b1295","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1474-4422(11)70305-2","article-title":"Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study","volume":"11","author":"Connick","year":"2012","journal-title":"The Lancet Neurology."},{"key":"10.1016\/j.addr.2023.115161_b1300","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s11055-012-9593-z","article-title":"Transplantation of mesenchymal stem cells in multiple sclerosis","volume":"42","author":"Odinak","year":"2012","journal-title":"Neurosci. Behav. Physiol."},{"key":"10.1016\/j.addr.2023.115161_b1305","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jcyt.2016.08.007","article-title":"Clinical safety of intrathecal administration of mesenchymal stromal cell\u2013derived neural progenitors in multiple sclerosis","volume":"18","author":"Harris","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.addr.2023.115161_b1310","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ebiom.2018.02.002","article-title":"Phase I trial of intrathecal mesenchymal stem cell-derived neural progenitors in progressive multiple sclerosis","volume":"29","author":"Harris","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2023.115161_b1315","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/cns.12759","article-title":"Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: clinical, ophthalmological and radiological assessments of safety and efficacy","volume":"23","author":"Dahbour","year":"2017","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.addr.2023.115161_b1320","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458517703802","article-title":"Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis","volume":"24","author":"Cohen","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.addr.2023.115161_b1325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-018-1433-7","article-title":"Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis","volume":"16","author":"Riordan","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.addr.2023.115161_b1330","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/08820139.2018.1504301","article-title":"Therapeutic use of intrathecal mesenchymal stem cells in patients with multiple sclerosis: a pilot study with booster injection","volume":"48","author":"Sahraian","year":"2019","journal-title":"Immunol. Invest."},{"key":"10.1016\/j.addr.2023.115161_b1335","first-page":"2102","article-title":"Short and long term clinical and immunologic follow up after bone marrow mesenchymal stromal cell therapy in progressive multiple sclerosis\u2014a phase I study, Journal of","volume":"8","author":"Iacobaeus","year":"2019","journal-title":"Clin. Med."},{"key":"10.1016\/j.addr.2023.115161_b1340","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/ar4520","article-title":"Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study","volume":"16","author":"Wang","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.addr.2023.115161_b1345","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/ard.2009.123463","article-title":"Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study","volume":"69","author":"Liang","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.addr.2023.115161_b1350","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/annrheumdis-2017-211073","article-title":"A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis","volume":"76","author":"Deng","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.addr.2023.115161_b1355","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s13287-022-02941-w","article-title":"Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I\/II randomized placebo-controlled clinical trial","volume":"13","author":"Izadi","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.addr.2023.115161_b1360","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-023-05934-3","article-title":"Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a Phase I\/II randomised double-blind placebo-controlled trial","author":"Carlsson","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.addr.2023.115161_b1365","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.it.2020.11.001","article-title":"Tolerogenic Dendritic Cells in Autoimmunity and Inflammatory Diseases","volume":"42","author":"Morante-Palacios","year":"2021","journal-title":"Trends Immunol."},{"key":"10.1016\/j.addr.2023.115161_b1370","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.4049\/jimmunol.1302350","article-title":"1, 25-Dihydroxyvitamin D3 promotes tolerogenic dendritic cells with functional migratory properties in NOD mice","volume":"192","author":"Ferreira","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2023.115161_b1375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-019-1541-1","article-title":"Jolanta Keliris, Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA","volume":"16","author":"Derdelinckx","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.addr.2023.115161_b1380","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/imm.12776","article-title":"1, 25-dihydroxyvitamin D3-induced dendritic cells suppress experimental autoimmune encephalomyelitis by increasing proportions of the regulatory lymphocytes and reducing T helper type 1 and type 17 cells","volume":"152","author":"Xie","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.addr.2023.115161_b1385","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02068","article-title":"Matured Tolerogenic Dendritic Cells Effectively Inhibit Autoantigen Specific CD4+ T Cells in a Murine Arthritis Model","volume":"10","author":"Jansen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2023.115161_b1390","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2337\/dc11-0472","article-title":"Phase I (Safety) Study of Autologous Tolerogenic Dendritic Cells in Type 1 Diabetic Patients","volume":"34","author":"Giannoukakis","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2023.115161_b1395","doi-asserted-by":"crossref","unstructured":"I. Zubizarreta, G. Fl\u00f3rez-Grau, G. Vila, R. Cabez\u00f3n, C. Espa\u00f1a, M. Andorra, A. Saiz, S. Llufriu, M. Sepulveda, N. Sola-Valls, E.H. Martinez-Lapiscina, I. Pulido-Valdeolivas, B. Casanova, M. Martinez Gines, N. Tellez, C. Oreja-Guevara, M. Espa\u00f1ol, E. Trias, J. Cid, M. Juan, M. Lozano, Y. Blanco, L. Steinman, D. Benitez-Ribas, P. Villoslada, Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial, Proceedings of the National Academy of Sciences. 116 (2019) 8463\u20138470. 10.1073\/pnas.1820039116.","DOI":"10.1073\/pnas.1820039116"},{"key":"10.1016\/j.addr.2023.115161_b1400","doi-asserted-by":"crossref","first-page":"e030309","DOI":"10.1136\/bmjopen-2019-030309","article-title":"RESTORE consortium, Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration","volume":"9","author":"Willekens","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.addr.2023.115161_b1405","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/annrheumdis-2018-eular.2880","article-title":"SAT0212 The safety and tolerability of intra-articular injection of tolerogenic dendritic cells in patients with rheumatoid arthritis: the preliminary results","volume":"77","author":"Kurochkina","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.addr.2023.115161_b1410","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2015-208456","article-title":"Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis","volume":"76","author":"Bell","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.addr.2023.115161_b1415","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa9301","article-title":"Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype\u2013positive rheumatoid arthritis patients","volume":"7","author":"Benham","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2023.115161_b1420","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clim.2014.04.006","article-title":"Myeloid-derived suppressor cells are increased in frequency but not maximally suppressive in peripheral blood of Type 1 Diabetes Mellitus patients","volume":"153","author":"Whitfield-Larry","year":"2014","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.addr.2023.115161_b1425","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/03009742.2012.716450","article-title":"Increased circulating myeloid-derived suppressor cells correlated negatively with Th17 cells in patients with rheumatoid arthritis","volume":"42","author":"Jiao","year":"2013","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.addr.2023.115161_b1430","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/annrheumdis-2014-205508","article-title":"Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis","volume":"75","author":"Guo","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.addr.2023.115161_b1435","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1189\/jlb.4A0314-139R","article-title":"Myeloid-derived suppressor cells regulate T cell and B cell responses during autoimmune disease","volume":"97","author":"Crook","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.addr.2023.115161_b1440","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s10753-013-9783-z","article-title":"Myeloid-Derived Suppressor Cells Protect Mouse Models from Autoimmune Arthritis via Controlling Inflammatory Response","volume":"37","author":"Zhang","year":"2014","journal-title":"Inflammation"},{"key":"10.1016\/j.addr.2023.115161_b1445","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.clim.2015.02.001","article-title":"Myeloid-derived suppressor cells are proinflammatory and regulate collagen-induced arthritis through manipulating Th17 cell differentiation","volume":"157","author":"Zhang","year":"2015","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.addr.2023.115161_b1450","doi-asserted-by":"crossref","first-page":"5828","DOI":"10.4049\/jimmunol.0903636","article-title":"Myeloid-Derived Suppressor Cells Prevent Type 1 Diabetes in Murine Models","volume":"185","author":"Yin","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2023.115161_b1455","doi-asserted-by":"crossref","first-page":"e100013","DOI":"10.1371\/journal.pone.0100013","article-title":"Evaluation of the Therapeutic Potential of Bone Marrow-Derived Myeloid Suppressor Cell (MDSC) Adoptive Transfer in Mouse Models of Autoimmunity and Allograft Rejection","volume":"9","author":"Drujont","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2023.115161_b1460","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaut.2018.06.002","article-title":"Hematopoietic stem cell therapy for autoimmune diseases \u2013 Clinical experience and mechanisms","volume":"92","author":"Alexander","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.addr.2023.115161_b1465","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/ar2128","article-title":"Cell therapy for autoimmune diseases","volume":"9","author":"Dazzi","year":"2007","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.addr.2023.115161_b1470","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.beha.2006.09.008","article-title":"Autoimmunity following haematopoietic stem-cell transplantation","volume":"20","author":"Daikeler","year":"2007","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.addr.2023.115161_b1475","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1177\/1352458511434067","article-title":"No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients","volume":"18","author":"Lutterotti","year":"2012","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.addr.2023.115161_b1480","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/1352458512438454","article-title":"A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper","volume":"18","author":"Saccardi","year":"2012","journal-title":"Mult Scler."},{"key":"10.1016\/j.addr.2023.115161_b1485","doi-asserted-by":"crossref","first-page":"eabq1693","DOI":"10.1126\/scitranslmed.abq1693","article-title":"Dynamics of T cell repertoire renewal following autologous hematopoietic stem cell transplantation in multiple sclerosis","volume":"14","author":"Ruder","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2023.115161_b1490","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200027","article-title":"B-Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis","volume":"9","author":"von Niederh\u00e4usern","year":"2022","journal-title":"Neurology - Neuroimmunology Neuroinflammation."},{"key":"10.1016\/j.addr.2023.115161_b1495","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2337\/dc11-2161","article-title":"Diabetic ketoacidosis at diagnosis influences complete remission after treatment with hematopoietic stem cell transplantation in adolescents with type 1 diabetes","volume":"35","author":"Gu","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2023.115161_b1500","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/jama.2009.470","article-title":"C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus","volume":"301","author":"Couri","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2023.115161_b1505","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.2337\/db14-0295","article-title":"Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: a multicenter analysis","volume":"63","author":"D\u2019Addio","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2023.115161_b1510","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1210\/jc.2015-2776","article-title":"Long-Term Insulin Independence in Type 1 Diabetes Mellitus Using a Simplified Autologous Stem Cell Transplant","volume":"101","author":"Cant\u00fa-Rodr\u00edguez","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.addr.2023.115161_b1515","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0140-6736(00)02627-1","article-title":"Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study","volume":"356","author":"Traynor","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2023.115161_b1520","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1002\/art.10594","article-title":"Hematopoietic stem cell transplantation for severe and refractory lupus","volume":"46","author":"Traynor","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2023.115161_b1525","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.autrev.2017.03.008","article-title":"Autologous hematopoietic stem cell transplantation in Systemic Lupus Erythematosus and antiphospholipid syndrome: A systematic review","volume":"16","author":"Leone","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.addr.2023.115161_b1530","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1038\/sj.bmt.1703944","article-title":"Hematopoietic stem cell transplantation for severe rheumatoid arthritis","volume":"32","author":"Moore","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.addr.2023.115161_b1535","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2006-08-042820","article-title":"Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells","volume":"109","author":"Al-toma","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.addr.2023.115161_b1540","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"Treg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol."},{"key":"10.1016\/j.addr.2023.115161_b1545","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri1032","article-title":"Natural versus adaptive regulatory T cells","volume":"3","author":"Bluestone","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2023.115161_b1550","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4049\/jimmunol.173.1.236","article-title":"CD4+ CD25+ regulatory T cell repertoire formation in response to varying expression of a neo-self-antigen","volume":"173","author":"Lerman","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2023.115161_b1555","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.immuni.2004.07.009","article-title":"Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors","volume":"21","author":"Hsieh","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2023.115161_b1560","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2337\/db06-1248","article-title":"No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes","volume":"56","author":"Brusko","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2023.115161_b1565","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.2337\/diabetes.54.5.1407","article-title":"Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes","volume":"54","author":"Brusko","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2023.115161_b1570","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20060772","article-title":"Groth, CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells","volume":"203","author":"Liu","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.addr.2023.115161_b1575","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-065X.2008.00637.x","article-title":"Human regulatory T cells: role in autoimmune disease and therapeutic opportunities","volume":"223","author":"Brusko","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.addr.2023.115161_b1580","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajt.2023.06.012","article-title":"Donor antigen-specific regulatory T cell administration to recipients of live donor kidneys: A ONE Study consortium pilot trial","author":"Guinan","year":"2023","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.addr.2023.115161_b1585","unstructured":"CAR T Cells: Engineering Immune Cells to Treat Cancer - NCI, (2013). https:\/\/www.cancer.gov\/about-cancer\/treatment\/research\/car-t-cells (accessed August 1, 2023)."},{"key":"10.1016\/j.addr.2023.115161_b1590","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661875","article-title":"Antigen-Specific Regulatory T Cell Therapy in Autoimmune Diseases and Transplantation","volume":"12","author":"Selck","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2023.115161_b1595","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108409","article-title":"A new approach in the treatment of autoimmune diseases","volume":"102","author":"Beheshti","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.addr.2023.115161_b1600","first-page":"eaba6884","article-title":"Shattering barriers toward clinically meaningful MSC therapies, Science","volume":"6","author":"Levy","year":"2020","journal-title":"Advances"},{"key":"10.1016\/j.addr.2023.115161_b1605","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nbt.2816","article-title":"Mesenchymal stem cells: immune evasive, not immune privileged","volume":"32","author":"Ankrum","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2023.115161_b1610","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/art.27736","article-title":"Fibroblast growth factor 2 and platelet-derived growth factor, but not platelet lysate, induce proliferation-dependent, functional class II major histocompatibility complex antigen in human mesenchymal stem cells","volume":"62","author":"Bocelli-Tyndall","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2023.115161_b1615","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","article-title":"Mesenchymal stromal cells: clinical challenges and therapeutic opportunities","volume":"22","author":"Galipeau","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.addr.2023.115161_b1620","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.2147\/DDDT.S225613","article-title":"Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy for Rheumatoid Arthritis Patients: A Prospective Phase I\/II Study","volume":"13","author":"Wang","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.addr.2023.115161_b1625","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/sctm.18-0031","article-title":"Intravenous Infusion of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Rheumatoid Arthritis: A Phase Ia Clinical Trial","volume":"7","author":"Park","year":"2018","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.addr.2023.115161_b1630","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2015-208918","article-title":"Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib\/IIa clinical trial","volume":"76","author":"\u00c1lvaro-Gracia","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.addr.2023.115161_b1635","first-page":"82","article-title":"A review of clinical trials: mesenchymal stem cell transplant therapy in type 1 and type 2 diabetes mellitus","volume":"7","author":"Cho","year":"2018","journal-title":"Am J Stem Cells."},{"key":"10.1016\/j.addr.2023.115161_b1640","article-title":"Mesenchymal stem cells to treat type 1 diabetes, Biochimica et Biophysica Acta (BBA) -","author":"Pixley","year":"1866","journal-title":"Molecular Basis of Disease."},{"key":"10.1016\/j.addr.2023.115161_b1645","article-title":"Mesenchymal Stem Cell Therapy: Hope for Patients With Systemic Lupus Erythematosus","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2023.115161_b1650","doi-asserted-by":"crossref","first-page":"11592","DOI":"10.3390\/ijms222111592","article-title":"Mesenchymal Stem Cell-Based Therapy for Rheumatoid Arthritis","volume":"22","author":"Sarsenova","year":"2021","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.addr.2023.115161_b1655","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221100294","article-title":"Cell-based therapies for rheumatoid arthritis: opportunities and challenges","volume":"14","author":"Li","year":"2022","journal-title":"Therapeutic Advances in Musculoskeletal."},{"key":"10.1016\/j.addr.2023.115161_b1660","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.632717","article-title":"Therapeutic Use of Mesenchymal Stromal Cells: The Need for Inclusive Characterization Guidelines to Accommodate All Tissue Sources and Species","volume":"9","author":"Wright","year":"2021","journal-title":"Front Cell Dev Biol."},{"key":"10.1016\/j.addr.2023.115161_b1665","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103058","article-title":"Mesenchymal stromal cells: Getting ready for clinical primetime","volume":"60","author":"Wobma","year":"2021","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.addr.2023.115161_b1670","series-title":"Potency Assays for Advanced Stem Cell Therapy Medicinal Products","first-page":"139","article-title":"Illustrative Potency Assay Examples from Approved Therapies","author":"Torrents","year":"2023"},{"key":"10.1016\/j.addr.2023.115161_b1675","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41586-019-1802-2","article-title":"An acute immune response underlies the benefit of cardiac stem cell therapy","volume":"577","author":"Vagnozzi","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2023.115161_b1680","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2023.115161_b1685","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol."},{"key":"10.1016\/j.addr.2023.115161_b1690","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","article-title":"Myeloid-derived suppressor cells coming of age","volume":"19","author":"Veglia","year":"2018","journal-title":"Nat Immunol."},{"key":"10.1016\/j.addr.2023.115161_b1695","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aae0482","article-title":"Arginase-1\u2013dependent promotion of TH17 differentiation and disease progression by MDSCs in systemic lupus erythematosus","volume":"8","author":"Wu","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2023.115161_b1700","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1002\/art.39767","article-title":"Myeloid-derived suppressor cells induce the expansion of regulatory B cells and ameliorate autoimmunity in the sanroque mouse model of systemic lupus erythematosus","volume":"68","author":"Park","year":"2016","journal-title":"Arthritis & Rheumatology."},{"key":"10.1016\/j.addr.2023.115161_b1705","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41590-018-0237-5","article-title":"Myeloid-derived suppressor cells control B cell accumulation in the central nervous system during autoimmunity","volume":"19","author":"Knier","year":"2018","journal-title":"Nat Immunol."},{"key":"10.1016\/j.addr.2023.115161_b1710","first-page":"805","article-title":"Compliance in Non-Clinical Development of Cell-","volume":"11","author":"Lopez-Navas","year":"2022","journal-title":"Gene-, and Tissue-Based Medicines: Good Practice for Better Therapies, Stem Cells Translational Medicine."},{"key":"10.1016\/j.addr.2023.115161_b1715","doi-asserted-by":"crossref","first-page":"20150017","DOI":"10.1098\/rstb.2015.0017","article-title":"Cell-based therapy technology classifications and translational challenges","volume":"370","author":"Mount","year":"2015","journal-title":"Philos. Trans. R. Soc., B"},{"key":"10.1016\/j.addr.2023.115161_b1720","unstructured":"T.W. House, Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy, The White House. (2022). https:\/\/www.whitehouse.gov\/briefing-room\/presidential-actions\/2022\/09\/12\/executive-order-on-advancing-biotechnology-and-biomanufacturing-innovation-for-a-sustainable-safe-and-secure-american-bioeconomy\/ (accessed August 28, 2023)."},{"key":"10.1016\/j.addr.2023.115161_b1725","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.5045\/br.2023.2023015","article-title":"Practical issues in CAR T-cell therapy","volume":"58","author":"Byun","year":"2023","journal-title":"Blood Res."},{"key":"10.1016\/j.addr.2023.115161_b1730","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jcyt.2019.01.003","article-title":"Chimeric antigen receptor\u2013T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods","volume":"21","author":"Harrison","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.addr.2023.115161_b1735","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s11899-019-00522-y","article-title":"Towards Automated Manufacturing for Cell Therapies","volume":"14","author":"Smith","year":"2019","journal-title":"Curr Hematol Malig Rep."},{"key":"10.1016\/j.addr.2023.115161_b1740","doi-asserted-by":"crossref","unstructured":"R. Borgert, Improving outcomes and mitigating costs associated with CAR T-cell therapy, Am J Manag Care. 27 (2021) S253\u2013S261. 10.37765\/ajmc.2021.88737.","DOI":"10.37765\/ajmc.2021.88737"},{"key":"10.1016\/j.addr.2023.115161_b1745","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114003","article-title":"Understanding and improving cellular immunotherapies against cancer: From cell-manufacturing to tumor-immune models","volume":"179","author":"Ringquist","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.115161_b1750","first-page":"464","article-title":"A good manufacturing practice method to ex vivo expand natural killer cells for clinical use","volume":"13","author":"Torelli","year":"2015","journal-title":"Blood Transfus."},{"key":"10.1016\/j.addr.2023.115161_b1755","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jcyt.2018.05.001","article-title":"Manufacturing development and clinical production of NKG2D chimeric antigen receptor\u2013expressing T cells for autologous adoptive cell therapy","volume":"20","author":"Murad","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.addr.2023.115161_b1760","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/14653249.2010.515582","article-title":"A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer","volume":"13","author":"Geller","year":"2011","journal-title":"Cytotherapy"},{"key":"10.1016\/j.addr.2023.115161_b1765","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004131","article-title":"FDA Oversight of Cell Therapy Clinical Trials","volume":"4","author":"Au","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2023.115161_b1770","doi-asserted-by":"crossref","first-page":"879","DOI":"10.5966\/sctm.2014-0122","article-title":"Proceedings: International Regulatory Considerations on Development Pathways for Cell Therapies","volume":"3","author":"Feigal","year":"2014","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.addr.2023.115161_b1775","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.stem.2011.05.013","article-title":"Hematopoietic Stem Cell Transplantation and Implications for Cell Therapy Reimbursement","volume":"8","author":"Maziarz","year":"2011","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.addr.2023.115161_b1780","unstructured":"NICE issues final guidance on axitinib (Inlyta) and sipuleucel-T (Provenge) | Press and media | News, NICE. (n.d.). https:\/\/www.nice.org.uk\/news\/press-and-media\/nice-issues-final-guidance-on-axitinib-inlyta-and-sipuleucel-t-provenge (accessed August 28, 2023)."},{"key":"10.1016\/j.addr.2023.115161_b1785","unstructured":"N. Crabb, Evaluation and reimbursement of regenerative medicines and cell therapies, Regenerative Medicine Translation\u2013a Pathway into Clinical Practice. London, UK. 10 (2014)."},{"key":"10.1016\/j.addr.2023.115161_b1790","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/10428194.2022.2147395","article-title":"Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy \u2013 a retrospective cohort study using CMS 100% Medicare claims database","volume":"64","author":"Yang","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.addr.2023.115161_b1795","unstructured":"ChondroCelect, Characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins, (n.d.)."},{"key":"10.1016\/j.addr.2023.115161_b1800","unstructured":"autologous_chondrocyte_implantation, (n.d.)."},{"key":"10.1016\/j.addr.2023.115161_b1805","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.reth.2022.04.004","article-title":"Advanced Therapy medicinal products for autologous chondrocytes and comparison of regulatory systems in target countries","volume":"20","author":"Kim","year":"2022","journal-title":"Regen Ther."},{"key":"10.1016\/j.addr.2023.115161_b1810","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2217\/rme.15.51","article-title":"Bringing regenerative medicines to the clinic: the future for regulation and reimbursement","volume":"10","author":"Bubela","year":"2015","journal-title":"Regen. Med."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23004763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23004763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:39:26Z","timestamp":1759210766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X23004763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":362,"alternative-id":["S0169409X23004763"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2023.115161","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translation of cell therapies to treat autoimmune disorders","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2023.115161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115161"}}